Amador Bioscience

🎇 We're excited to share a real case study on the bioanalysis of ADC drugs, featuring Andrea Ngai, Associate Director of Bioanalysis and Biomarkers-LCMS at Amador. In this first-in-human trial, Andrea explores three key forms of PK results: 🔬 Free Payload Concentration: Insights into toxicity effects 🔬 Intact ADC Concentration: Information on payload release 🔬 Antibody Scaffold Concentration: Indicator of antibody stability All methods were tested using triple quadrupole LC-MS. Want to learn more? Feel free to contact us! 📞 #Bioanalysis #ADCDrugs #ClinicalTrials #PKAnalysis #LCMS #AmadorBio

#Hiring 🔥 If you're interested in the Sample Operations & Clinical Kitting Lead position at our Maryland lab, apply today! Send your resume to: George Hristopoulos 📧 george.hristopoulos@amadorbio.com #CareerOpportunity #BiotechJobs #Bioanalysis #GLPLab

#Hiring 🚀 Great Opportunity to Join Our Team at Amador! 🚀 Our Maryland lab is looking for a Sample Operations & Clinical Kitting Lead, Senior Scientist. Ready to make an impact? Apply now by sending your resume to George Hristopoulos (george.hristopoulos@amadorbio.com) or James Hoy(james.hoy@amadorbio.com) #CareerOpportunity #BiotechJobs #JoinOurTeam #AmadorBio

🚀 Join the Amador Bioscience Team! We are excited to announce openings for QCP Team Leaders in our Belgium (Limburg) and China (Hangzhou) offices. If you are passionate about leading in the field of quantitative clinical pharmacology and meet the role requirements, we would love to hear from you! 📍 Limburg, Belgium: Hong Ma / Hong.Ma@AmadorBio.com 📍 Hangzhou, China: Pansy Qiu / Xumei.Qiu@AmadorBio.com Apply today by sending your resume to the contact person for the corresponding region. We look forward to welcoming you to our team of leaders!🌟 #Hiring #JobOpportunity #CareerOpportunity #ClinicalPharmacology #QuantitativePharmacology #TeamLeader #BelgiumJobs #ChinaJobs

📊 Amador Study Share 📊 Excited to share an Amador-involved study presented at ASCPT 2024. The poster focuses on #PopPK modeling of Camrelizumab in patients with various cancers, including advanced hepatocellular carcinoma. Through modeling PK data from 10 clinical studies, including the Phase III pivotal trial, the PK model showed that: 🔹 Exposure was generally proportional to dose over a 200-600 mg dose range. 🔹 Median time to >90% of steady-state exposure (AUC) was estimated as ~16 weeks following the start of camrelizumab 200 mg Q2W dosing. 🔹 The model estimated 2.3-fold accumulation from the first dose to steady-state. 🔹 An effective half-life based on the model-predicted accumulation ratio was estimated as ~17 days. 🔔 Learn more, please click https://lnkd.in/gZgfXnxw #Pharmacokinetics #Camrelizumab #ASCPT2024 #DrugDevelopment #AmadorBio #Innovation

📹 New Video Alert! In dosing strategy, it's crucial to consider not only PK/PD but also evaluate the immunogenicity of the drug to ensure its safety and efficacy. 💡In this video, Dr. Meina Liang, CTO of Amador, discusses the key considerations of dosing strategy. If you would like to learn more about Amador's solutions, please feel free to contact us.🚀   #PKPD #Immunogenicity #DosingStrategy #Pharmacology #DrugDevelopment #AmadorBio #Innovation

🌟 We are pleased to share the study we participated in, focusing on the #PopPK Modeling of NGM438 in patients with advanced/metastatic solid tumors. 🖥️METHODS: PK data from 25 subjects in a Phase 1/1b study of NGM438, either as a monotherapy or in combination with pembrolizumab, were simultaneously modeled using a population approach. We employed both M1 (excluding BLQ observations) and M3 (likelihood of BLQ observations) methods. Our findings revealed that the M3 method more accurately describes the PK characteristics of NGM438. 📅CONCLUSION: PK of NGM438 was typical for therapeutic monoclonal antibodies. Besides body weight, only baseline albumin level was identified as a relevant PK covariate. Age, sex, race and baseline peripheral blood mononuclear cell counts had no impact on NGM438 PK. To learn more, please visit 👇 https://lnkd.in/gFvD_Rtw #QuantitativePharmacology #ClinicalPharmacology #ProjectOptimus #Pharmacokinetics #ClinicalResearch #DrugDevelopment #Innovation

🌟 New Video Alert! 🌟 In our latest video, Meina Liang summarizes the current PK and immunogenicity analysis strategies for marketed #ADC drugs. 🔬 #PK: Routine detection methods include total antibody, ADC, and small molecule, with occasional exceptions.  🔍 #DDI: Usually assessed for small molecule drugs, but not for ADC drugs.  🧬 #Immunogenicity: ADC drugs have a low incidence of NAb, with a lower rate of domain-specific evaluation. Feel free to leave your comments, and let's discuss together! 💬 💡 To learn more, visit https://lnkd.in/gK5d8FpP #ADCDrugs #Pharmacokinetics #DrugDevelopment #Bioanalysis #Innovation #SmallMolecule

🌟 At the 3rd Annual #ADC x #XDC China Forum 2024 on July 3-4, Dr. Bing Wang, CEO of Amador, was honored to present at the Plenary Session. Dr. Wang's presentation focused on innovative strategies and addressed complex issues in ADC drug development, 💡 highlighting cutting-edge advances in quantitative pharmacology and translational science. Stay tuned for more updates from Amador as we continue to drive innovation in ADC drug development! 🚀 #QuantitativePharmacology #Pharmacology #TranslationalScience #ADCDrugs #DrugDevelopment #Innovation

📢 Highlights from the #CBA-China Dr. Bing Wang, CEO of Amador, was invited to attend and present on "Strategies and Challenges in #ClinicalPharmacology and #Bioanalysis of #ADC Drugs." and to participate in a roundtable discussion on the opportunities and challenges of ADC clinical operations. In his presentation, Dr. Wang discussed: 🔬 The complexity and risks of ADC development 💊 Primary focus on #FIH (First-In-Human) dose selection 📊 Clinical PK & ER for dose optimization 🚀 Introduction to new frontiers and new technology platforms We are working on videos of the presentation that will be shared soon. Stay tuned to Amador for updates or leave a comment about what you are interested in! #ProjectOptimus #Biomarkers #Toxicology #DrugDevelopment #ClinicalOperations